Comparative Pharmacology
Head-to-head clinical analysis: MILPROSA versus ORAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MILPROSA versus ORAP.
MILPROSA vs ORAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
Orap (pimozide) is a diphenylbutylpiperidine antipsychotic that selectively blocks dopamine D2 receptors in the central nervous system, with weak antagonism at alpha1-adrenergic and H1-histamine receptors. Its anti-dyskinetic effect in Tourette syndrome may also involve blockade of calcium channels.
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
Initial: 2 mg orally twice daily; maintenance: 2-10 mg twice daily. Maximum 20 mg/day.
None Documented
None Documented
Clinical Note
moderateVorapaxar + Tranilast
"Vorapaxar may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateVorapaxar + Resveratrol
"Vorapaxar may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateVorapaxar + Nimesulide
"Vorapaxar may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateVorapaxar + Epoprostenol
"Vorapaxar may increase the antiplatelet activities of Epoprostenol."
14 hours (range 10–18); prolonged in renal impairment (up to 40 hours)
Terminal elimination half-life is 20–40 hours (mean 27 hours). Steady-state achieved in 4–7 days.
Renal (70% unchanged, 20% as inactive metabolites); fecal (10%)
Primarily hepatic metabolism; approximately 40% excreted in urine as metabolites, 15% in feces as unchanged drug and metabolites.
Category C
Category C
Antipsychotic
Antipsychotic